Objectives: The objective of this clinical study was to evaluate the effect of a bisphosphonate coating on a titanium implant on the implant stability quotient (ISQ) and the radiographic marginal bone levels at implants during early healing (2-8 weeks).
| INTRODUC TI ON
Bisphosphonates reduce osteoclast activity. After implant insertion in cancellous bone, bisphosphonates reduce osteoclast activity while leaving osteoblast activity unchanged. In animal experiments, this leads to a positive formation/resorption balance, so that the implant becomes surrounded by more and denser bone, leading to better fixation (Andersson, Agholme, Aspenberg, & Tengvall, 2010; Kellesarian, Subhi Alharthi, Saleh Binshabaib, & Javed, 2017; Skoglund, Holmertz, & Aspenberg, 2004; Tengvall, Skoglund, Askendal, & Aspenberg, 2004; Wermelin, Suska, Tengvall, Thomsen, & Aspenberg, 2008) . This effect can be achieved by applying the bisphosphonate as a coating on the implant (Abtahi, Tengvall, & Aspenberg, 2012; Toksvig-Larsen & Aspenberg, 2013) .
In a previous clinical trial, we found that dental implants coated with a fibrinogen layer with the bisphosphonates pamidronate and ibandronate showed considerably higher ISQ values 6 months after insertion than the uncoated controls (Abtahi et al., 2012) . This was a strong proof of concept, but its clinical value remained to be shown. In principle, bisphosphonate coatings on dental implants could serve two purposes. One would be to accelerate osseointegration, thus allowing earlier load bearing. The other would be to serve as a protection against marginal resorption and thereby possibly against the risk of ensuing peri-implantitis. Recently, we reported the radiographic findings after 1 and 5 years of load bearing by bisphosphonate-coated dental implants. The bisphosphonate-coated implants showed less marginal resorption than uncoated controls after 5 years of use of the implants (Abtahi, Henefalk, & Aspenberg, 2016 ). This suggests a prolonged preservation of the marginal bone.
Zoledronate is about 1,000 times more potent than pamidronate.
Moreover, we have tested the stability of metal screws coated with zoledronate in a previous animal study (Abtahi, Agholme, Sandberg, & Aspenberg, 2013) . The zoledronate-coated screws had the best fixation when using removal torque and showed less bone loss on micro-CT. Furthermore, Andersson et al. (2010) showed significantly increased mechanical implant fixation after 2 and 6 weeks of implantation with zoledronate-coated screws in a rat model by using pullout force. This suggests that even a very high local bisphosphonate activity can be tolerated in the bone adjacent to metal implants, as no signs of osteonecrosis were observed with zoledronate-coated screws.
However, the clinical benefits of this technique in dentistry are not known. One could speculate that if bisphosphonates have an effect in the early phase of healing, then rehabilitation after implantation would become faster. This hypothesis needed to be tested, so we performed the present study.
In relation to our previous 6-month trial using Brånemark implants, this time we tested the Osseospeed microthreaded Astra
Tech
® dental implant and a new coating, containing a more potent bisphosphonate, zoledronate, applied manually by a method that was later slightly modified and standardized to become a proprietary method (Zolidd ® ). Astra Tech ® implants are sand-blasted and treated with fluoride ions (being highly electronegative). Previous research revealed that a microthreaded design may promote osseointegration (Berglundh, Abrahamsson, Albouy, & Lindhe, 2007; Lee, Choi, Park, Kim, & Moon, 2007) .
The implants are at risk of loosening during the critical time at the early stages in the development of osseointegration. Several authors have found only slight changes in stability during the first 2 weeks, followed by the typical decrease in stability from week 2 to weeks 4-6 (Balshi, Allen, Wolfinger, & Balshi, 2005; Barewal, Oates, Meredith, & Cochran, 2003; Friberg, Sennerby, Meredith, & Lekholm, 1999; Nedir, Bischof, Szmukler-Moncler, Bernard, & Samson, 2004; Schätzle et al., 2009 ).
Previously, we found that Brånemark dental implants coated with pamidronate and ibandronate showed a better fixation than the uncoated controls (Abtahi et al., 2012) . In this study trial, we used Astra Tech implants coated with a stronger bisphosphonate (zoledronate). We tested whether a zoledronate coating could accelerate osseointegration, without any signs of osteonecrosis of the jaw (ONJ). We anticipated that the controls would show decreasing ISQ values during the first few weeks after implantation due to post-operative bone resorption and we hypothesized that the coating would prevent this dip.
| MATERIAL AND ME THODS
Patients in need of at least two dental implants in the upper jaw were invited to participate in the present study. Power calculation showed that a sample size of at least sixteen patients would be needed.
Twenty consecutive patients were asked to participate in this study. Howell classes IV-VI (Cawood & Howell, 1988) ; (c) receiving bone graft; and (d) having undergone tooth extraction <1 year before implant surgery. In patients requiring a third implant, the implant position that did not have equivalent jawbone was excluded from the study. For example, for a patient in need of implants in positions 13, 23, and 25, the implants in positions 13 and 23 were included in the study and the implant in position 25 was excluded. The number of patients was predetermined by a power analysis based on a previous study (Abtahi et al., 2012) . The study was approved by the Regional Committee for Ethics in Linköping, Sweden (2012/240-31).
| Implant coating procedure
We used 32 Astra Tech microthreaded dental implants with
Osseospeed surface with 3.5 diameters and 11 mm in length.
Sixteen implants were coated with a fibrinogen multilayer incorporating zoledronic acid in a process modified from Tengvall et al. CSL Behring, Germany) for 10 min at 50°C and then in 2 mg/ml zoledronic acid for 30 min. After drying and single packaging in double-peel pouches, all the implants were sterilized with γ-irradiation at 17-25 kGy (Beta-Gamma Service, Wiehl, Germany).
The bisphosphonate-coated implants and uncoated implants were visually indistinguishable.
| Surgery and resonance frequency measurement
The surgery was performed by JA, using local anesthesia, at the Department of Maxillofacial Surgery, Linköping University Hospital.
Of the 16 patients, six were in need of three implants and 10 patients needed two implants. The surgeon chose two implantation sites (regardless of whether the patient required two or three implants) that he considered to be as similar as possible, and named them A and B.
A nurse outside the room, who was not otherwise involved in the treatment or in the study, opened a non-transparent randomization envelope. She then delivered either a coated or a control implant for insertion at site A, and the other for site B, depending on the instructions in the envelope. After delivering the implants, the nurse placed a paper with the patient's personal identity number and name in the envelope and sealed it again. The envelopes were then stored by the monitor until data lock and unblinding. Thus, the trial was performed double-blind-except for the nurse, who was otherwise uninvolved.
Implant positions are given in Table 1 . The preparation of the implant site involved several steps. Initially, a round bur was used to open a defect through the marginal cortical bone. The preparation was continued with two consecutive drills (Astra Tech 2-mm, 2.7-mm, and 3.2-mm). Finally, Astra Tech 3.5-mm implants were inserted and closed with cover screws before the flap was repositioned and sutured. Implant lengths of 11 mm were used.
After insertion, a resonance frequency analyzer (Osstell Mentor;
Integration Diagnostics, Gothenburg, Sweden) was used to measure the implant stability quotient (ISQ) of non-submerged implants with the transducer oriented perpendicular to the long axis of the implant at implant insertion and at 2, 4, 6, and 8 weeks ( Figure 1b which reviewed all procedures during the study and checked data before data lock and unblinding. The second and third authors may have had possible bias due to economic interests, but they had no contact with the patients or the data between enrollment of the first patient and data lock. AddBIO AB provided the coatings, but was not otherwise involved in planning, conduction, or financing of the study.
| Radiographic measurements
The examination of marginal bone level was performed using digital receptor technique (Shick CDR Elite; Sirona Dental Systems GmbH, Bensheim, Germany) and diagnostic imaging (Sectra PACS; Sectra F I G U R E 1 (a) A "SmartPeg" transducer attached on an abutment for measurement of right maxillary implants. Different RFA orientations: perpendicular (b) and parallel (c). Healing caps covered the implants during the study period (d)
AB, Linköping, Sweden). Digital radiographic films were taken at implant insertion and at abutment connection (8 weeks) from each individual implant using a long-cone technique in order to obtain the X-ray direction perpendicular to the film.
Altogether, 32 implants were inserted in 16 patients and intraoral radiographs were taken at implant insertion and at 8 weeks.
Sixty-two radiographs were analyzed by GH (except in one case).
The level of the marginal bone at the implant mesially and distally was estimated from a reference point on the implant to the first implant-bone contact (Figure 2 ). Marginal bone loss was defined as the maximum distance from the reference point on the implant side to the marginal bone. Change in bone level over time was expressed as the mean of changes on both sides of the implant. The second author was kept blind during this procedure.
| Qualitative evaluation of marginal bone defects
Bony defects were defined as space where the bottom of the pockets was apical to the alveolar crest. This space is bounded by alveolar wall and implant surface. For each implant, the presence of marginal bone defects was registered by an independent radiologist. Sixtytwo radiographs were evaluated by using ×5 magnification in the data program PACS.
| Bench test and ISQ calibration
When the clinical results were evaluated, it became clear that the ISQ values were unrealistically low. It turned out that the SmartPeg that we had used was not calibrated for the necessary abutment. A bench calibration was therefore performed as follows. An implant of the same sort as that used in the study was fixed between two heavy steel blocks pressed together in a vice, so that the entire implant was held. The arrangement was checked for precision using an operation microscope. The implant was enveloped in eight layers of latex from a surgical glove, to give an elastic fixation. By gradually increasing the pressure of the vice, stiffer and stiffer fixation could be obtained. 
| Power analysis
In this study, we used split-mouth design. The power of the study was 0.90%. A previous study showed an SD of 5.3 for the difference between coated and uncoated implants. We assumed that a difference of five ISQ units was clinically relevant. For evaluation of sample size, we used Statistica software version 13.
| Statistics
Evaluation was based on internal controls. The hypothesis was that zoledronate-coated implants would not show any decrease in ISQ throughout the entire study period (0-8 weeks), while the uncoated implants would drop in stability (ISQ) during the early healing phase. 
| RE SULTS

| ISQ values
One hundred forty-eight double-resonance frequency measurements were performed in 16 patients. Patient 14 missed the 4-week follow-up (Table 1) .
The mean ISQ value of all implants at insertion was 74 for both coated and uncoated implants (SD 6.1 and 5.6, respectively). The mean values remained between 74 and 78 for both implants at all time points throughout the study. There was no significant difference between coated and uncoated implants at any time point. Figure 3 shows overlapping confidence interval which indicates no difference between the groups. Only one implant showed the expected decrease after a few weeks. This was a coated implant with the lowest value (40) after 4 weeks, recovering to 65 at 8 weeks.
One control implant suddenly dropped to 44 at 8 weeks. All other values were over 65.
The primary outcome was a difference in ISQ of 2.9 (SD 6.7), meaning a slight disadvantage for the coated implants that was not 
| Marginal bone level
One of the authors (GH) performed the radiographic evaluation. The exploratory blinded qualitative scoring of marginal pockets showed some degree of marginal bone defects formation in 13 of 15 uncoated implants and in two of 15 coated implants (p = 0.003).
Most marginal bone defects were small.
| Exclusion
The excluded patient, who lost her implant, consulted her general dentist three times in the first week after surgery because the temporary prosthesis did not fit, and several adjustment attempts were made. Still, at follow-up visit with the surgeon after 2 weeks, the prosthesis was found to cause loading of the implant. At 4 weeks, the ISQ was 57. The implant was grossly loose at 6 weeks. At the removal, no granulation tissue was seen around the screw. A new implant (4.2 mm in diameter) was inserted after a healing period of 3 months and it osseointegrated uneventfully.
| D ISCUSS I ON
The aim of this study was to determine whether a bisphosphonate coating would prevent the temporary decrease in fixation quality that is often described to follow a few weeks after implantation.
We failed to show this, as no decrease in ISQ values occurred even for the control implants. This may have been related to implant design features, with consequences that were unknown when our study started in 2013. However, as a secondary outcome, we found decreased marginal resorption at coated implants, as in our previous study (Abtahi et al., 2012) . This effect was small, as measured in millimeters, but might be qualitatively important, as the resorption was reduced to almost zero with the coating.
The marginal resorption around control implants had the shape of pockets. Such pocket formation appeared to be prevented by the bisphosphonate coating.
We have previously reported the results of a randomized trial with bisphosphonate-coated dental implants (Abtahi et al., 2012) .
Each patient received one coated and one uncoated Brånemark implant in a paired, double-blind fashion. After 6 months for osseointegration, implant-supported dental prostheses were applied, and the patients could start chewing. The analysis of resonance frequency indicated better fixation of the coated implants at that time point.
Moreover, we also found a statistically significant reduction in marginal bone resorption both 2 months after insertion and after five years of functional loading (Abtahi et al., 2016) . The reliability of the bisphosphonate coating procedure was tested in a previous pilot study in rats (J. Abtahi, P. Aspenberg, & F. Agholme, unpublished data). Three rats received a zoledronate-coated screw, and the reliability of the coating procedure was tested by screwing and unscrewing an implant in extraction sockets. Implant insertion trauma did not have any influence on this layer, as measured by ellipsometry and scintillation.
In the present study, there was no drop in ISQ for coated and uncoated implants. There was no significant difference in implant stability between these two groups. The negative finding for the primary outcome (ISQ) in the present trial was unexpected, considering our previous, clearly positive results with Brånemark implants at 6 months. It appears to have been due to the fact that the expected decrease in the controls after a few weeks never occurred, despite the fact that such a decrease has been shown for various implant designs in numerous studies (Balshi et al., 2005; Barewal et al., 2003; Friberg et al., 1999; Nedir et al., 2004; Schätzle et al., 2009; Simmons et al., 2017) . gen layers alone do not enhance the osseointegration (Andersson et al., 2010) . The coating technique for dental implants in this study has been described by our team previously (Andersson et al., 2010) . Briefly, a cross-linked multilayer of fibrinogen was covalently bound to the metal, and then zoledronic acid was bound and adsorbed to the fibrinogen matrix. The authors showed that zoledronate-coated screws had a stronger implant fixation than controls without bisphosphonate. Furthermore, no difference was found between fibrinogen-only coated screws and non-coated stainless steel screws when measuring pull-out force.
The ISQ values reported here must be interpreted with caution.
Even though there was a strong correlation between values obtained with incorrectly and correctly applied SmartPegs (r = 0.998), this was in a bench test and may not reflect a similar correlation in vivo. Still, it is reasonable to assume that differences between pairs of implants in the same patient would also have been detected with a systematic error in ISQ values.
The absence of the expected primary outcome was not due to a lack of bisphosphonate effects. The coating obviously exerted some biological effects, as judged by the marginal resorption findings. Still, the question remains as to whether we would have been able to reproduce the higher ISQ values at 6 months from our previous dental Marginal bone loss originates from a combination of biological and mechanical factors (Oh, Yoon, Misch, & Wang, 2002) . Primary implant stability is a mechanical phenomenon influenced by factors related to the implant (the design and dimensions of the fixture), the patient (the quality and quantity of bone), and the operator (the surgical technique). Primary implant stability is highest just after implant placement, because of mechanical compression of the fixture on bone walls, and it decreases with time. Secondary stability is the progressive increase in stability related to biological events at the bone-implant interface, such as new bone formation and remodeling (Raghavendra, Wood, & Taylor, 2005) .
Moreover, surface-modified implants show an increased amount of bone formation (Buser et al., 2004) . One approach is coating of the implant surface with bisphosphonate in order to enhance the implant-bone contact and increase the primary stability in the early phases of osseointegration. The stability of the metal screws coated with zoledronate has already been studied (Abtahi et al., 2012; Kellesarian et al., 2017) . Furthermore, Andersson et al. (2010) found significantly increased mechanical implant fixation after two and six weeks of implantation with zoledronate-coated screws in a rat model, using pull-out force. This suggests that even a very high degree of local bisphosphonate activity can be tolerated in the bone adjacent to metal implants, as there were no signs of osteonecrosis with zoledronate-coated screws.
In the present study, we used Osseospeed microthreaded Astra Tech ® dental implants, which are sand-blasted and treated with fluoride ions. The presence of fluoride ions on the implant surface increases the density of the bone, which is favorable from a mechanical point of view (Lee et al., 2007) . The long-term effect of the Microthread™ implants on the maintenance of marginal bone level has been evaluated in previous studies (Lee et al., 2007;  Van de Velde, Collaert, Sennerby, & Bruyn, 2010 ). It appears that immediately loaded implants with microthread design at the coronal part of the implant lead to improved bone preservation in the maxilla without affecting the edentulous mandible ( Van de Velde et al., 2010) .
One coated implant in the present study loosened. This is a caveat. However, we had clearly documented that this implant was troublesome already in the first week and that it was inadvertently loaded. We therefore consider it unlikely that the loosening was related to the coating. The fact that a new implant could be successfully implanted 3 months later is also reassuring. The bisphosphonate that must have remained in the bone after the first implant appears not to have interfered with healing of the defect or with osseointegration of the new implant.
The present study had some weaknesses. The stability of the bisphosphonate-coated dental implants has been tested in the maxilla in this study and in several previous studies. CT scan was performed preoperatively to determine the bone volume and shape of the jawbone. Although the study design was based on internal controls, our knowledge of the bone quality at the implant sites was poor. Following implant placement, a small amount of marginal bone resorption occurs and these small changes are considered to be part of a physiological process. In the present study, a small clinical difference can be regarded as being negligible. The clinical consequences of our findings therefore remain speculative. However, in highly demanding cases such as implants in the anterior maxilla, preservation of the marginal bone level is critical for an "esthetic" result. Furthermore, the influence of implant design on the outcome of this trial was not clear. The number of patients was based on a previous study (Abtahi et al., 2012) investigating ISQ changes within 6 months, whereas in the present study, we focused on the early healing. One can speculate that the power calculation was questionable. However, this was the first study of bisphosphonate-coated implants in the early healing phase.
| CON CLUS ION
There were no statistically significant differences observed in ISQ values between the coated and uncoated implants during the early healing. However, less marginal bone loss was identified on radiographs at the coated implants. 
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